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Abstract
Objective: Cardiovascular disease is the leading cause of mortality in women in the United States. Aggressive
treatment of modifiable risk factors (e.g., hypercholesterolemia) is essential in reducing disease burden. Despite
guidelines recommending the use of statin treatment in hypercholesterolemic women, this patient group is often
undertreated. This subgroup analysis of the Statin Therapies for Elevated Lipid Levels compared Across doses
to Rosuvastatin (STELLAR) trial examines the effects of statin therapy in hypercholesterolemic women.
Methods: As part of the STELLAR trial, 1,146 women with elevated low-density lipoprotein cholesterol (LDL-C
‡160 and <250mg/dL) and triglycerides <400mg/dL were randomized to rosuvastatin 10–40mg, atorvastatin
10–80mg, simvastatin 10–80mg, or pravastatin 10–40mg for 6 weeks.
Results: LDL-C reduction with rosuvastatin 10mg, atorvastatin 10mg, simvastatin 20mg, and pravastatin 40mg
was 49%, 39%, 37%, and 30%, respectively, after 6 weeks. High-intensity statins (rosuvastatin 20–40mg and
atorvastatin 40–80mg) reduced LDL-C to the greatest extent: 53% with rosuvastatin 20mg, 57% with rosu-
vastatin 40mg, 47% with atorvastatin 40mg, and 51% with atorvastatin 80mg. Similar results were observed for
non-high-density lipoprotein cholesterol (non-HDL-C). Increases in HDL-C were greater with rosuvastatin across
doses than with other statins. All treatments were well tolerated, with similar safety profiles across dose ranges.
Conclusions: Statin therapies in the STELLAR trial led to reductions in LDL-C, non-HDL-C, and triglycerides
and increases in HDL-C among hypercholesterolemic women, with rosuvastatin providing the greatest
reductions in LDL-C and non-HDL-C.
Introduction
Cardiovascular disease (CVD) is the leading cause ofmortality among women in the United States.1 While cor-
onary heart disease (CHD) rates in women increase markedly
withage,2,3 ofparticularconcern is the increasingnumberofCHD
deaths amongUSwomen aged 35–54 years, believed to be due to
the increasing prevalence of obesity.4 Therefore, early identifi-
cation and aggressive management of modifiable risk factors are
essential to reduce the overall burden of CHD in women.5
Hypercholesterolemia is a major modifiable risk factor for
CVD for both men and women.3 Low-density lipoprotein
cholesterol (LDL-C) levels are typically lower in women than
in men until menopause, when levels increase (from a mean of
117mg/dL [3mmol/L] to 145mg/dL [3.7mmol/L])6 and LDL
particles tend to become more atherogenic.7 High-density li-
poprotein cholesterol (HDL-C) levels are approximately
10mg/dL (0.3mmol/L) higher in women than in men,8 and
low levels are more predictive of CHD in women compared
with men, especially in women aged 65 years or older.3
Moreover, elevated triglycerides may be a more significant
risk factor in women (especially older women) compared with
men,4,9,10 and, for both sexes, elevated non-HDL-C is recog-
nized as a risk marker for CHD,11 particularly in patients with
hypertriglyceridemia, reflecting increased levels of athero-
genic remnant very low-density lipoprotein (VLDL).
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Several guidelines recommend statins as first-line treat-
ment for cholesterol reduction when diet and exercise are
inadequate.4,12 Ameta-analysis of 27 statin trials showed that
a 39mg/dL (1mmol/L) reduction in LDL-C was associated
with a 16% (rate ratio 0.84, 99% confidence interval [CI]
0.78–0.91) reduction in major vascular events in women,
similar to the 22% (rate ratio 0.78, 99% CI 0.75–0.81) re-
duction observed in men.13 Further analysis of 5 studies
comparing more versus less intensive statin therapy revealed
that major vascular events were reduced by 25% (rate ratio
0.75, 99% CI 0.58–0.97) per 39mg/dL (1mmol/L) reduction
in LDL-C in women receiving more versus less intensive
statin therapy, compared with 29% (rate ratio 0.71, 99% CI
0.63–0.80) in men.13 Thus, although women derive a clear
benefit from LDL-C reduction,14–16 available data indicate
that women are undertreated for hypercholesterolemia.17,18
One reason for undertreatment may be underestimation of
CVD risk in women. Standard risk stratification tools, such as
the Framingham risk score, are limited in that they focus on
short-term (i.e., 10-year) risk of myocardial infarction and
CHD death only, exclude family history, and overestimate or
underestimate risk in non-white populations. This, together
with the fact that subclinical CVD can have relatively high
prevalence among women, means that many women under
the age of 75 years may never exceed a predicted 10-year risk
for CHD of ‡10% and subsequently may not be considered
for dyslipidemia treatment.4
Mindful of these limitations, the 2011 American Heart
Association (AHA) evidence-based guidelines for CVD pre-
vention in women recommend defining high risk in women as
a 10-year risk of ‡10% for all CVD, not just CHD alone.4 The
guidelines also recommend that all women should be encour-
aged to reach ideal levels of four critical lipid parameters
(Table 1) through lifestyle approaches.4 For high-risk women
(i.e., those with CHD, cerebrovascular disease, peripheral ar-
terial disease, abdominal aortic aneurysm, end-stage or chronic
kidney disease, diabetes mellitus, or a predicted 10-year CVD
risk ‡10%), the addition of lipid-lowering pharmacotherapy is
recommended if lifestyle changes alone are insufficient at re-
ducing lipids to the ideal levels.4
More recently the AHA, in collaboration with the American
College of Cardiology (ACC), published guidelines on the
treatment of cholesterol to reduce atherosclerotic cardiovas-
cular risk in adults (men and women).12 These guidelines
identify patients and provide treatment recommendations ac-
cording to four statin-benefit groups (Tables 2, 3).
The Statin Therapies for Elevated Lipid Levels compared
Across doses to Rosuvastatin (STELLAR) trial (clinical-
trials.gov identifier: NCT00654537) compared rosuvastatin
treatment with three other widely used statins (atorvastatin,
simvastatin, and pravastatin) in a hypercholesterolemic pa-
tient population.19 This subgroup analysis examines the
effects of statin therapy in improving lipid profiles in the hy-
percholesterolemic women who participated in the STELLAR
trial. Because of its large number of female participants (51%,
n= 1,146), the STELLAR trial is particularly appropriate for
this analysis.
Materials and Methods
The STELLAR trial was a randomized, parallel-group,
open-label, comparator-controlled multicenter trial in 2,431
hypercholesterolemic patients. A detailed description of the
methods of the trial is provided elsewhere.19 Briefly, after a
6-week dietary lead-in period, men and women aged 18 years
Table 1. American Heart Association’s
Recommended Lipid Parameters for Women
Lipid Recommended level
LDL-C <100mg/dL (<2.6mmol/L)
HDL-C >50mg/dL (>1.3mmol/L)
Triglycerides <150mg/dL (<1.7mmol/L)
Non-HDL-C <130mg/dL (<3.4mmol/L)
Source: Mosca et al., 2011.4
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-
density lipoprotein cholesterol.
Table 2. American College of Cardiology/
American Heart Association
Statin-Benefit Groups
Statin-benefit group Recommendation
Clinical ASCVD Age £75 years: high-
intensity statin
Age >75 years or
not candidate for high-
intensity statin:
moderate-intensity statin
Primary elevations of
LDL-C ‡190mg/dL
(4.9mmol/L)
High-intensity statin
(moderate-intensity statin
if not candidate for high-
intensity statin)
Diabetes aged 40–75
years and LDL-C
70–189mg/dL
(1.8–4.1mmol/L), but
without clinical ASCVD
Moderate-intensity statin
Estimated 10-year ASCVD
risk ‡7.5%: high-intensity
statin
Without clinical ASCVD
or diabetes with LDL-C
70–189mg/dL
(1.8–4.1mmol/L) and
estimated 10-year
ASCVD risk ‡7.5%
Moderate- to high-intensity
statin
Source: Stone et al., 2014.12
ASCVD, atherosclerotic cardiovascular disease; LDL-C, low-
density lipoprotein cholesterol.
Table 3. American College of Cardiology/
American Heart Association Statin
Intensity Guidelines
Intensity Statin dose
Anticipated LDL-C
reduction
High Rosuvastatin 20–40mg ‡50%
Atorvastatin 40–80mg
Moderate Rosuvastatin 5–10mg 30%–50%
Atorvastatin 10–20mg
Source: Stone et al., 2014.12
LDL-C, low-density lipoprotein cholesterol.
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or older with fasting LDL-C ‡160mg/dL and <250mg/dL
(‡4.1mmol/L and <6.5mmol/L) and triglycerides<400mg/dL
(<4.5mmol/L), discontinued from all cholesterol-lowering
drugs and dietary supplements, were randomized to 6 weeks of
treatment with one of four statins.
The current subgroup analysis involves 1,146 women who
began study treatment with rosuvastatin 10, 20, or 40mg;
atorvastatin 10, 20, 40, or 80mg; simvastatin 10, 20, 40, or
80mg; or pravastatin 10, 20, or 40mg. To be included, all
women had to have a baseline and at least one post-baseline
lipid measurement. Changes in LDL-C, non-HDL-C,
triglycerides, and HDL-C from baseline to 6 weeks were
assessed by statin dose group. To compare changes in lipid
levels among treatments, least-squares mean changes from
baseline to 6 weeks for 22 pairwise comparisons of rosuva-
statin 10, 20, or 40mg with milligram-equivalent or higher
doses of comparator statins (Fig. 1) were obtained using a
Bonferroni adjustment with a significance level of 0.002 to
obtain an experiment-wise error rate of 0.05. This is an
adjustment for the 22multiple comparisons (0.05/22 = 0.002).
For efficacy variables, the last observation was carried for-
ward for those women not completing 6 weeks of treatment.
Safety evaluations are described in Jones et al.19 and involved
assessment of clinical adverse events and laboratory values.
Results
Patients
Of the 1,146 women in this subgroup analysis from the
STELLAR trial, 249 received rosuvastatin 10–40mg, 320
received atorvastatin 10–80mg, 333 received simvastatin
10–80mg, and 244 received pravastatin 10–40mg. Baseline
characteristics are shown in Table 4. Mean ages, 58–60 years,
were similar across the statin groups. Most of these women
were taking at least one concomitant medication. At baseline,
mean LDL-C was 190mg/dL (4.9mmol/L), indicating that
the women had substantial hypercholesterolemia.
Efficacy
Statin treatment produced dose-related decreases in LDL-
C levels ranging from 21% to 57% at 6 weeks, depending on
the statin and dose used (Fig. 2A). At the lowest statin dose,
10mg, LDL-C was reduced by 49% with rosuvastatin, 39%
with atorvastatin, 30% with simvastatin, and 21% with
pravastatin ( p< 0.002 rosuvastatin vs. all comparators). A
similar pattern was observed for the high-intensity doses
of statins defined by the ACC/AHA guideline and re-
commended for those at risk of atherosclerotic cardiovascular
disease:12 LDL-C reductions were 53% with rosuvastatin
20mg, 57% with rosuvastatin 40mg, 47% with atorvastatin
40mg, and 51% with atorvastatin 80mg. Rosuvastatin 20mg
produced statistically greater reductions in LDL-C compared
with atorvastatin 20mg and 40mg ( p < 0.002 for both
comparisons). In addition, rosuvastatin 40mg produced
statistically greater reductions in LDL-C compared with
atorvastatin 40mg ( p< 0.002).
Reductions in non-HDL-C levels ranged from 45% to 53%
with rosuvastatin, 37% to 48%with atorvastatin, 27% to 44%
with simvastatin, and 19% to 28% with pravastatin (Fig. 2B).
Reductions in non-HDL-C with rosuvastatin 10mg were
significantly greater when compared with atorvastatin 10mg;
simvastatin 10, 20, or 40mg; and pravastatin 10, 20, or 40mg
( p < 0.002 for all comparisons). Rosuvastatin 20mg reduced
non-HDL-C significantly more than milligram-equivalent
doses of atorvastatin, simvastatin, and pravastatin ( p < 0.002
for all comparisons).
The increases in HDL-C were numerically greater with
rosuvastatin thanwith the other statins, but the differenceswere
not statistically significant, except that rosuvastatin 20 and
40mg increased HDL-C significantly more than milligram-
equivalent or higher doses of atorvastatin (Fig. 2C).
All statins reduced triglyceride levels, with similar effects
across the dose range for rosuvastatin and atorvastatin, and a
trend for dose-related reductions for simvastatin and prava-
statin. No significant differences in effect on triglycerides were
observed between rosuvastatin and atorvastatin. However,
rosuvastatin 10mg decreased triglycerides significantly more
than simvastatin 10mg, and pravastatin 10mg and 20mg;
rosuvastatin 20mg decreased triglycerides significantly more
than 20mg of simvastatin and pravastatin (Fig. 2D) ( p< 0.002
for all comparisons).
Safety
All treatments were generally well tolerated, with similar
safety profiles across treatments and dose ranges (Table 5).
Study withdrawal due to drug-related treatment-emergent
adverse events occurred in 5 rosuvastatin-treated women
(2.0%), 13 atorvastatin-treated women (4.1%), 7 simvastatin-
treated women (2.1%), and 7 pravastatin-treated women
(2.9%). The most common adverse events were pain (6.4%),
pharyngitis (5.4%), headache (4.4%), and myalgia (4.0%).
There were no cases of rhabdomyolysis, myopathy, or clin-
ically significant elevations (>10 times the upper limit of
normal) in serum creatine kinase in these women. Clinically
significant elevations (>3 times the upper limit of normal on
two consecutive occasions) in alanine aminotransferase were
infrequent, occurring in 1 patient receiving atorvastatin
20mg (1.3%), 2 patients receiving atorvastatin 80mg (2.4%),
and 1 patient receiving simvastatin 80mg (1.2%). No patients
in this analysis had creatinine levels that increased >100%
from baseline, and no women had creatinine levels that were
above the upper limit of normal.
FIG. 1. Pairwise comparisons for changes in lipids and
achievement of lipid levels for rosuvastatin versus atorva-
statin, simvastatin, and pravastatin.
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Discussion
To our knowledge, this is the first large-scale comparative
subgroup analysis of the lipid-lowering effects of statins
across their dose ranges in hypercholesterolemic women in
a clinical trial population. As in the total STELLAR
population,19,20 rosuvastatin 10–40mg reduced LDL-C and
non-HDL-C more than milligram-equivalent doses of ator-
vastatin, and milligram-equivalent and higher doses of
simvastatin and pravastatin. In our analysis, mean baseline
LDL-C was 190mg/dL (4.9mmol/L), indicating that the
women had substantial hypercholesterolemia, with many of
them fulfilling the ACC/AHA 2013 guideline criteria for
high-intensity statin therapy according to their baseline LDL-C
levels alone, irrespective of other risk factors.
Although the 2011 AHA and 2013 ACC/AHA lipid
guidelines represent important directives in preventive
cardiovascular care for women4,12 and awareness of CVD
among women has increased over the last couple of decades,
significant gaps in the understanding and management of the
disease remain, particularly among black and Hispanic
women.4,9,18,19,21 Indeed, the majority of women (approxi-
mately 85%) in the STELLAR trial were white, and so results
from this and other statin studies need to be interpreted with
caution in women of ethnic minorities.
In addition, Mosca and colleagues have established that
women with high cardiovascular risk rarely achieve
established lipid goals in clinical practice.21 At a mean
follow-up of 27 months in 8,353 high-risk women (CHD,
CHD risk equivalent, or chronic kidney disease) in a man-
aged care setting, only 7% had achieved AHA ideal lipid
levels (12% after 36 months). Despite the substantial evi-
dence available during the study period that lipid-modifying
therapy would benefit these women, such treatment was
initiated in only 32% of patients, including 35% with LDL-C
‡100mg/dL (‡2.6mmol/L).
Some of this undertreatment may be due to the
misconception that risk factors in premenopausal women
do not need to be managed aggressively and to the earlier
belief, now disproved,22–24 that hormone replacement therapy
reduced cardiovascular risk in postmenopausal women. Some
undertreatment may be due to lack of awareness of overall
Table 4. Baseline Characteristics of 1,146 Women in the STELLAR Trial (Randomized Population)
Rosuvastatin
10–40mg
Atorvastatin
10–80mg
Simvastatin
10–80mg
Pravastatin
10–40mg
(n= 249) (n = 320) (n= 333) (n= 244)
Age (years)
Mean (SD) 60 (12) 60 (11) 59 (12) 58 (12)
>65 years, n (%) 87 (35) 131 (41) 111 (33) 80 (33)
Race, %
White 85 82 84 85
Black 8 12 10 12
Hispanic 5 3 4 2
Other 1 3 2 2
Atherosclerosis, n (%)a 35 (14) 46 (14) 50 (15) 27 (11)
Diabetes, n (%) 15 (6) 27 (8) 26 (8) 22 (9)
Hypertension, n (%) 111 (45) 165 (52) 166 (50) 113 (46)
Smoking history, n (%)
Current smoker 38 (15) 52 (16) 43 (13) 33 (14)
Former smoker 63 (25) 95 (30) 108 (32) 80 (33)
Family history of premature
CHD/PVD, n (%)
56 (23) 68 (21) 72 (22) 59 (24)
Concomitant medications
(pre-enrollment), n (%)b
247 (99) 308 (96) 323 (97) 238 (98)
Lipid and Apo values at baseline,
mg/dL; mean (SD)c
LDL-C 192 (19) 190 (20) 191 (19) 189 (17)
Non-HDL-C 229 (22) 226 (24) 225 (23) 226 (23)
HDL-C 55 (11) 55 (12) 55 (12) 53 (12)
Triglycerides 184 (69) 179 (66) 171 (60) 189 (69)
Apo B 174 (23) 171 (24) 168 (23) 171 (24)
Apo A-I 160 (27) 163 (27) 161 (28) 158 (27)
Apo B/Apo A-I 1.1 (0.2) 1.1 (0.2) 1.1 (0.2) 1.1 (0.2)
aHistory of angina, myocardial infarction, cerebrovascular accident, transient ischemic attack, or intermittent claudication, or any
documented carotid artery, peripheral vascular, or coronary artery disease.
bThe most common concomitant medications were 3-hydroxy-3-methylglutaryl-coenzyme A (HMG CoA) reductase inhibitors (39.9%);
analgesics and antipyretics, salicylic acid and derivatives (29.7%); multivitamins, other combinations (25.3%); other plain vitamin
preparations (22.8%); calcium supplement (21.3%); analgesics, antipyretics, anilides (20.2%); propionic acid derivatives (20.2%); natural
and semisynthetic estrogens (16.5%); thyroid hormones (13.4%); selective serotonin reuptake inhibitors (13.3%); COX-2 inhibitors
(12.8%); proton pump inhibitors (12.7%); ACE inhibitors (11.4%); ascorbic acid (vitamin C) (11.4%).
cNumbers of patients for whom lipid data are available are 247, 317, 330, and 239 for rosuvastatin, atorvastatin, simvastatin, and
pravastatin, respectively; number available for apolipoproteins are 241, 309, 326, and 235, respectively.
Apo, apolipoprotein; PVD, peripheral vascular disease; SD, standard deviation; STELLAR, Statin Therapies for Elevated Lipid Levels
compared Across doses to Rosuvastatin.
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cardiovascular risk in women18 and to differences in presen-
tation and diagnosis of CVD in women compared with men.3
Our 6-week treatment period was not long enough to assess
the effect on clinical events; therefore, our data cannot sug-
gest a preferential advantage of one statin versus another in
preventing cardiovascular events. However, based on the
Cholesterol Treatment Trialists’ meta-analysis of >170,000
patients in 26 prospective, randomized statin trials, which
showed that every 39mg/dL reduction in LDL-C led to a 22%
(95% CI: 0.76–0.80, p< 0.0001) reduction in major vascular
Table 5. Adverse Events of Women in the STELLAR Trial (Randomized Population)
Rosuvastatin
10–40mg
Atorvastatin
10–80mg
Simvastatin
10–80mg
Pravastatin
10–40mg
AEs, n (%) (n= 250) (n = 320) (n= 331) (n = 244)
All AEs 110 (44.0) 181 (56.6) 168 (50.8) 130 (53.3)
AEs leading to death 0 0 0 0
AEs leading to withdrawal 7 (2.8) 14 (4.4) 10 (3.0) 8 (3.3)
Serious AEs 2 (0.8) 4 (1.3) 4 (1.2) 1 (0.4)
Drug-related AEs 28 (11.2) 53 (16.6) 36 (10.9) 25 (10.2)
Drug-related AEs leading to death 0 0 0 0
Drug-related AEs leading to withdrawal 5 (2.0) 13 (4.1) 7 (2.1) 7 (2.9)
Drug-related serious AEs 0 0 0 0
AEs, adverse events.
FIG. 2. (A) LS mean % change from baseline in LDL-C at week 6 (LOCF). (B) LS mean % change from baseline in non-
HDL-C at week 6 (LOCF). (C) LS mean % change from baseline in HDL-C at week 6 (LOCF). (D) LS mean % change
from baseline in TG at week 6 (LOCF). The dashed line refers to the least-squares mean percentage change for rosuvastatin
10mg. HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LOCF, last observation
carried forward; LS, least-squares; TG, triglycerides
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events and a 10% (95% CI: 0.87–0.93, p < 0.0001) reduction
in all-cause mortality,15 it would be predicted that greater
LDL-C reductions would confer greater benefit in reducing
cardiovascular events. Although women have been under-
represented in clinical end-point trials of statins, analyses of
subgroups of women from these trials indicate that LDL-C
reduction decreased cardiovascular event rates to a similar
degree in women compared with that documented in
men.14,16,25
A meta-analysis of 18 randomized controlled trials of
statins in primary prevention found that statin intervention
was associated with a lower cardiovascular event rate versus
control and was similar in women and men (odds ratio [OR]
0.81, 95% CI: 0.75–0.89; p < 0.0001 vs. OR 0.77, 95% CI:
0.71–0.83; p < 0.0001, respectively).14 In addition, a sex-
specific analysis of data from the Justification for the Use of
Statins in Prevention: An Intervention Trial Evaluating Ro-
suvastatin ( JUPITER) study assessed the efficacy and safety
of rosuvastatin in apparently healthy individuals with raised
high-sensitivity C-reactive protein.25 Overall, the absolute
CVD rates in women for rosuvastatin and placebo (0.57 and
1.04, respectively) were lower than those in men (0.88 and
1.54, respectively), although the relative risk reduction
associated with rosuvastatin was similar in women and men
(hazard ratio [HR] 0.54, 95% CI: 0.37–0.80; p = 0.002 vs. HR
0.58, 95% CI: 0.45–0.73; p < 0.001).25
Another meta-analysis compared the effect of statins in
secondary prevention of CVD in men and women in 11
trials.16 Statin therapy (atorvastatin, fluvastatin, lovastatin,
pravastatin, or simvastatin) was shown to be associated with a
reduced risk of cardiovascular events in all outcomes for
women (risk ratio [RR] 0.81, 95% CI 0.74–0.89) and men
(RR 0.82, 95% CI 0.78–0.85). However, there was no benefit
with regard to stroke and all-cause mortality in women,
although there was in men.16
Data on the impact of statin treatment on carotid intima-
media thickness are equally limited. A small study of 51
postmenopausal women aged ‡55 years with dyslipidemia
showed that women who received rosuvastatin 2.5mg per
day for 12 months had significantly lower carotid intima-
media thickness values when compared with the women
who received no statin therapy.26 These changes were in
conjunction with significant decreases in LDL-C and high-
sensitivity C-reactive protein.
Overall, statins have proved to be generally well tolerated
in most patients.27,28 Safety data from a number of large-
scale statin trials, when analyzed by gender, indicate that
statins are generally well tolerated in women.14,16 Taken
together, the available efficacy and safety data indicate that
dyslipidemic women should receive appropriate statin therapy
to reduce LDL-C levels and thereby reduce risk of CVD.
Conclusion
Our subanalysis of the STELLAR study confirms that
women can achieve effective LDL-C reduction with statin
therapy. Mean reductions in LDL-C were ‡49% with
rosuvastatin doses of 10mg or higher, ‡39%with atorvastatin
10mg or higher, ‡30% with simvastatin 10mg or higher, and
‡21% with pravastatin 10mg or higher. Moreover, statin
therapy was generally well tolerated in the women included
in this study. These results suggest that substantial
improvements in lipid levels are achievable with moderate-
to high-intensity statin therapy.
Acknowledgments
The authors would like to acknowledge Eric Justice of
BioScience Communications, New York, New York, and
Kerren Davenport, Prime Medica Ltd, Knutsford, Cheshire,
United Kingdom, for editorial assistance in the preparation
of this article funded by AstraZeneca, and Mike Palmer,
formerly of AstraZeneca, for his assistance with statistical
analyses. We would also like to acknowledge James Blasetto,
MD, for his contributions to the design of the STELLAR trial.
Each author has participated in the research and/or article
preparation. All authors have approved the final article.
This research was supported by AstraZeneca.
Author Disclosure Statement
SJL has served as a consultant for AstraZeneca, Pfizer, and
Merck and as an investigator for AstraZeneca and Pfizer.
VAC and DAA are employees of AstraZeneca. KEF and
FKW have no disclosures.
References
1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and
stroke statistics—2014 update: A report from the American
Heart Association. Circulation 2014;129:e28–e292.
2. Eaker ED, Chesebro JH, Sacks FM, et al. Cardiovascular
disease in women. Circulation 1993;88:1999–2009.
3. Welty FK. Cardiovascular disease and dyslipidemia in
women. Arch Intern Med 2001;161:514–522.
4. Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based
guidelines for the prevention of cardiovascular disease in
women—2011 update: A guideline from the American
Heart Association. Circulation 2011;123:1243–1262.
5. Kannel WB, Wilson PW. Efficacy of lipid profiles in pre-
diction of coronary disease. Am Heart J 1992;124:768–774.
6. Johnson CL, Rifkind BM, Sempos CT, et al. Declining
serum total cholesterol levels among US adults. The
National Health and Nutrition Examination Surveys. JAMA
1993;269:3002–3008.
7. Carr MC, Kim KH, Zambon A, et al. Changes in LDL
density across the menopausal transition. J Investig Med
2000;48:245–250.
8. Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of
coronary heart disease and lipoprotein cholesterol levels.
The Framingham Study. JAMA 1986;256:2835–2838.
9. Le NA, Brown WV, Davis WW, et al. Comparison of the
relation of triglyceride-rich lipoproteins and muscular
artery compliance in healthy women versus healthy men.
Am J Cardiol 2005;95:1049–1054.
10. Austin MA, Hokanson JE, Edwards KL. Hypertriglycer-
idemia as a cardiovascular risk factor. Am J Cardiol 1998;
81:7B–12B.
11. Third Report of the National Cholesterol Education Pro-
gram (NCEP) Expert Panel on Detection, Evaluation, and
Treatment of High Blood Cholesterol in Adults (Adult
Treatment Panel III) final report. Circulation 2002;106:
3143–3421.
12. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/
AHA guideline on the treatment of blood cholesterol to
reduce atherosclerotic cardiovascular risk in adults: A
report of the American College of Cardiology/American
STATIN EFFICACY AND SAFETY IN WOMEN: STELLAR 55
Heart Association Task Force on Practice Guidelines. J Am
Coll Cardiol 2014;63:2889–2934.
13. Fulcher J, O’Connell R, Voysey M, et al. Efficacy and
safety of LDL-lowering therapy among men and women:
Meta-analysis of individual data from 174,000 participants
in 27 randomised trials. Lancet 2015;385:1397–1405.
14. Kostis WJ, Cheng JQ, Dobrzynski JM, Cabrera J, Kostis
JB. Meta-analysis of statin effects in women versus men.
J Am Coll Cardiol 2012;59:572–582.
15. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety
of more intensive lowering of LDL cholesterol: A meta-
analysis of data from 170,000 participants in 26 randomised
trials. Lancet 2010;376:1670–1681.
16. Gutierrez J, Ramirez G, Rundek T, Sacco RL. Statin therapy
in the prevention of recurrent cardiovascular events: A sex-
based meta-analysis. Arch Intern Med 2012;172:909–919.
17. Schrott HG, Bittner V, Vittinghoff E, Herrington DM,
Hulley S. Adherence to National Cholesterol Education
Program Treatment goals in postmenopausal women with
heart disease. The Heart and Estrogen/Progestin Replace-
ment Study (HERS). The HERS Research Group. JAMA
1997;277:1281–1286.
18. Mosca L, Hammond G, Mochari-Greenberger H, Towfighi
A, Albert MA. Fifteen-year trends in awareness of heart
disease in women: Results of a 2012 American Heart
Association national survey. Circulation 2013;127:1254–1263.
19. Jones PH, Davidson MH, Stein EA, et al. Comparison of
the efficacy and safety of rosuvastatin versus atorvastatin,
simvastatin, and pravastatin across doses (STELLAR*
Trial). Am J Cardiol 2003;92:152–160.
20. Jones PH, Hunninghake DB, Ferdinand KC, et al. Effects
of rosuvastatin versus atorvastatin, simvastatin, and
pravastatin on non-high-density lipoprotein cholesterol,
apolipoproteins, and lipid ratios in patients with hyper-
cholesterolemia: Additional results from the STELLAR
trial. Clin Ther 2004;26:1388–1399.
21. Mosca L, Merz NB, Blumenthal RS, et al. Opportunity for
intervention to achieve American Heart Association
guidelines for optimal lipid levels in high-risk women in a
managed care setting. Circulation 2005;111:488–493.
22. Herrington DM, Reboussin DM, Brosnihan KB, et al.
Effects of estrogen replacement on the progression of
coronary-artery atherosclerosis. N Engl J Med 2000;343:
522–529.
23. Grady D, Herrington D, Bittner V, et al. Cardiovascular
disease outcomes during 6.8 years of hormone therapy:
Heart and Estrogen/progestin Replacement Study follow-up
(HERS II). JAMA 2002;288:49–57.
24. Hulley S, Grady D, Bush T, et al. Randomized trial
of estrogen plus progestin for secondary prevention of
coronary heart disease in postmenopausal women. Heart
and Estrogen/progestin Replacement Study (HERS)
Research Group. JAMA 1998;280:605–613.
25. Mora S, Glynn RJ, Hsia J, et al. Statins for the primary
prevention of cardiovascular events in women with
elevated high-sensitivity C-reactive protein or dyslipide-
mia: Results from the Justification for the Use of Statins in
Prevention: An Intervention Trial Evaluating Rosuvastatin
( JUPITER) and meta-analysis of women from primary
prevention trials. Circulation 2010;121:1069–1077.
26. Igase M, Kohara K, Tabara Y, et al. Low-dose rosuvastatin
improves the functional and morphological markers of
atherosclerosis in asymptomatic postmenopausal women
with dyslipidemia. Menopause 2012;19:1294–1299.
27. Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. ACC/
AHA/NHLBI clinical advisory on the use and safety of
statins. J Am Coll Cardiol 2002;40:567–572.
28. McKenney JM, Davidson MH, Jacobson TA, Guyton JR.
Final conclusions and recommendations of the National
Lipid Association Statin Safety Assessment Task Force.
Am J Cardiol 2006;97:89C–94C.
Address correspondence to:
Francine K. Welty, MD
Beth Israel Deaconess Medical Center
Harvard Medical School
330 Brookline Avenue (Masco 433)
Boston, MA 02215
E-mail: fwelty@bidmc.harvard.edu
56 WELTY ET AL.
